Israel
· Delayed Price · Currency is ILS · Price in ILA Dna Group (T.R.) Statistics
Total Valuation
TLV:DNA has a market cap or net worth of ILS 126.98 million. The enterprise value is 58.67 million.
| Market Cap | 126.98M |
| Enterprise Value | 58.67M |
Important Dates
The next estimated earnings date is Wednesday, May 28, 2025.
| Earnings Date | May 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TLV:DNA has 123.16 million shares outstanding. The number of shares has increased by 0.03% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 123.16M |
| Shares Change (YoY) | +0.03% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 36.56% |
| Owned by Institutions (%) | 0.18% |
| Float | 78.14M |
Valuation Ratios
The trailing PE ratio is 5.76.
| PE Ratio | 5.76 |
| Forward PE | n/a |
| PS Ratio | 414.97 |
| PB Ratio | 1.25 |
| P/TBV Ratio | 1.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 78.87 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 2.66 |
| EV / Sales | 191.74 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 60.77
| Current Ratio | 60.77 |
| Quick Ratio | 60.67 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 24.46% and return on invested capital (ROIC) is -1.04%.
| Return on Equity (ROE) | 24.46% |
| Return on Assets (ROA) | -1.02% |
| Return on Invested Capital (ROIC) | -1.04% |
| Return on Capital Employed (ROCE) | -1.46% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +18.02% in the last 52 weeks. The beta is -0.13, so TLV:DNA's price volatility has been lower than the market average.
| Beta (5Y) | -0.13 |
| 52-Week Price Change | +18.02% |
| 50-Day Moving Average | 103.90 |
| 200-Day Moving Average | 90.70 |
| Relative Strength Index (RSI) | 54.52 |
| Average Volume (20 Days) | 130,850 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TLV:DNA had revenue of ILS 306,000 and earned 22.10 million in profits. Earnings per share was 0.18.
| Revenue | 306,000 |
| Gross Profit | 306,000 |
| Operating Income | -1.51M |
| Pretax Income | 23.40M |
| Net Income | 22.10M |
| EBITDA | n/a |
| EBIT | -1.51M |
| Earnings Per Share (EPS) | 0.18 |
Balance Sheet
The company has 68.31 million in cash and n/a in debt, giving a net cash position of 68.31 million or 0.55 per share.
| Cash & Cash Equivalents | 68.31M |
| Total Debt | n/a |
| Net Cash | 68.31M |
| Net Cash Per Share | 0.55 |
| Equity (Book Value) | 101.47M |
| Book Value Per Share | 0.82 |
| Working Capital | 67.30M |
Cash Flow
| Operating Cash Flow | 1.61M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 100.00%, with operating and profit margins of -493.46% and 7,220.92%.
| Gross Margin | 100.00% |
| Operating Margin | -493.46% |
| Pretax Margin | 7,648.04% |
| Profit Margin | 7,220.92% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TLV:DNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.03% |
| Shareholder Yield | -0.03% |
| Earnings Yield | 17.40% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on November 10, 2019. It was a reverse split with a ratio of 0.1666666667.
| Last Split Date | Nov 10, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.1666666667 |
Scores
TLV:DNA has an Altman Z-Score of 20.88.
| Altman Z-Score | 20.88 |
| Piotroski F-Score | n/a |